Investor mix
12 investors on record; lead investors include Lilly Asia Ventures.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 2 | 17% |
| Private equity | 8 | 67% |
| Other / undisclosed | 2 | 17% |
Developer of therapies for the treatment of cancer, autoimmune and eye diseases
12 investors on record; lead investors include Lilly Asia Ventures.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 2 | 17% |
| Private equity | 8 | 67% |
| Other / undisclosed | 2 | 17% |